Text Size

The Satiety Effect After Okara Compared to Porridge Eating

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
Nutrigal LTD
Information provided by:
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT01075568
First received: February 17, 2010
Last updated: March 2, 2010
Last verified: February 2010
History of Changes
  Purpose

To examine the satiety effect after eating of Okara.


Condition Intervention
Healthy People
 Dietary Supplement: Nutrigal Okara - 100

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • To examine the satiety effect after 48 gram Okara compared to 40 gram of porridge eating. [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: March 2010
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Detailed Description:

This will be a single blind, cross-over design. Study population will include 10 subjects. The patients will be randomly assigned to receive one of two meals, 48 gram Okara or 40 gram (similar caloric value) semolina in two occasions (two visits). After the eating, the subject will stay in a closed room, without watch or any irritation. After three hours, the patient will fill a VAS questionnaire, and will get a standard meal. The meal will be weighed before and after.

Okara is a natural water extracted food grade soy product, contains approximately 35% protein (mfb), and about 43% of dietary fibers.

  Eligibility

Ages Eligible for Study:   20 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers
  • Age 20-65 years old
  • Written Informed Consent

Exclusion Criteria:

  • History of gastro-intestinal surgery
  • On medication that may influence gastric emptying, or medication for weight loss
  • Patient on PPI treatment, H2 Blockers or medication for weight loss
  • Known allergies to soy
  • Pregnancy or breast-feeding
  • Smoking
  • Athletes
  • Metabolic syndrome or diabetes mellitus
  • Family history of metabolic syndrome or diabetes mellitus
  • Weight loss > 2 kg during two months before the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01075568

Contacts
Contact: Nachum Vaisman, Prof' 009-972-3-6974807 vaisman@tasmc.health.gov.il

Locations
Israel
Tel Aviv Medical Center Not yet recruiting
Tel Aviv, Israel
Contact: Nachum Vaisman, Prof'     00-972-3-6974807     vaisman@tasmc.health.gov.il    
Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Nutrigal LTD
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01075568     History of Changes
Other Study ID Numbers: TASMC-10-NV-016-CTIL
Study First Received: February 17, 2010
Last Updated: March 2, 2010
Health Authority: Israel: Ministry of Health

ClinicalTrials.gov processed this record on May 19, 2013